Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines.

live attenuated vaccines lumpy skin disease lumpy skin disease vaccine vaccine evaluation

Journal

Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355

Informations de publication

Date de publication:
08 May 2021
Historique:
received: 31 03 2021
revised: 28 04 2021
accepted: 03 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

Vaccines form the cornerstone of any control, eradication and preventative strategy and this is no different for lumpy skin disease. However, the usefulness of a vaccine is determined by a multiplicity of factors which include stability, efficiency, safety and ease of use, to name a few. Although the vaccination campaign in the Balkans against lumpy skin disease virus (LSDV) was successful and has been implemented with success in the past in other countries, data of vaccine failure have also been reported. It was therefore the purpose of this study to compare five homologous live attenuated LSDV vaccines (LSDV LAV) in a standardized setting. All five LSDV LAVs studied were able to protect against a challenge with virulent LSDV. Aside from small differences in serological responses, important differences were seen in side effects such as a local reaction and a Neethling response upon vaccination between the analyzed vaccines. These observations can have important implications in the applicability in the field for some of these LSDV LAVs.

Identifiants

pubmed: 34066658
pii: vaccines9050473
doi: 10.3390/vaccines9050473
pmc: PMC8151199
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Bill and Melinda Gates Foundation
ID : Nr OPP1126866
Organisme : GALVmed
ID : Nr CAO-R34A0856
Organisme : Belgian Federal Public Service of Health, Food Chain Safety and Environment
ID : through the contract RT 15/3 (LUMPY SKIN 1)

Références

Vaccine. 2009 Mar 4;27(10):1500-3
pubmed: 19186204
Transbound Emerg Dis. 2017 Dec;64(6):1782-1789
pubmed: 27633121
J Virol Methods. 2017 Nov;249:48-57
pubmed: 28837841
Transbound Emerg Dis. 2018 Feb;65(1):174-185
pubmed: 28391652
Prev Vet Med. 2020 Aug;181:104595
pubmed: 30553537
BMC Vet Res. 2019 Jul 8;15(1):236
pubmed: 31286926
ILAR J. 2006;47(4):364-9
pubmed: 16963816
EFSA J. 2017 Apr 20;15(4):e04773
pubmed: 32625471
Transbound Emerg Dis. 2017 Aug;64(4):1268-1279
pubmed: 27039847
Trop Anim Health Prod. 2014 Jan;46(1):241-6
pubmed: 24097247
Arch Virol. 2019 Dec;164(12):2931-2941
pubmed: 31538254
Vet Rec. 1995 Jul 22;137(4):91-3
pubmed: 8533249
Vaccine. 2007 Mar 8;25(12):2238-43
pubmed: 17250934
Arch Virol. 2019 Dec;164(12):3107-3109
pubmed: 31529221
BMC Vet Res. 2015 Jun 17;11:135
pubmed: 26082259
Transbound Emerg Dis. 2018 Apr;65(2):491-496
pubmed: 29086485
Epidemiol Infect. 2013 Feb;141(2):425-30
pubmed: 22717050
Vet Rec. 1990 Dec 1;127(22):549-50
pubmed: 2281596
Transbound Emerg Dis. 2016 Apr;63(2):e213-9
pubmed: 25098267
Antiviral Res. 2013 May;98(2):261-5
pubmed: 23428671
Vaccine. 2015 Sep 11;33(38):4837-42
pubmed: 26238726
Vaccine. 2006 Feb 13;24(7):964-9
pubmed: 16242818
Transbound Emerg Dis. 2017 Jun;64(3):729-745
pubmed: 26564428
J Gen Virol. 2020 Jun;101(6):645-650
pubmed: 32391749
Onderstepoort J Vet Res. 2017 Mar 28;84(1):e1-e6
pubmed: 28397517
Prev Vet Med. 2011 Dec 15;102(4):274-83
pubmed: 21852008
Prev Vet Med. 2018 Nov 15;160:99-104
pubmed: 30389003
Transbound Emerg Dis. 2008 Sep;55(7):299-307
pubmed: 18503511
Genome Announc. 2016 Oct 20;4(5):
pubmed: 27795268
Vet Pathol. 2020 May;57(3):388-396
pubmed: 32314676
Transbound Emerg Dis. 2018 Oct;65(5):1137-1144
pubmed: 29932512
Prev Vet Med. 2020 Aug;181:104600
pubmed: 30581092
Vaccine. 2015 Jun 22;33(28):3256-61
pubmed: 26056063
Trop Anim Health Prod. 2013 Jun;45(5):1153-9
pubmed: 23274626
Antiviral Res. 2014 Sep;109:1-6
pubmed: 24973760
Genome Announc. 2016 Nov 10;4(6):
pubmed: 27834707
J Virol. 2002 Jun;76(12):6054-61
pubmed: 12021338
J Virol Methods. 2020 Mar;277:113800
pubmed: 31837373
Prev Vet Med. 2017 Nov 1;147:100-107
pubmed: 29254706
Transbound Emerg Dis. 2016 Jun;63(3):260-5
pubmed: 26991342
J Wildl Dis. 1992 Apr;28(2):295-300
pubmed: 1602585
J Virol Methods. 2013 Nov;193(2):446-51
pubmed: 23850698
J Vet Diagn Invest. 2007 Sep;19(5):486-91
pubmed: 17823391
Rev Sci Tech. 1994 Mar;13(1):195-216
pubmed: 8173096
Onderstepoort J Vet Res. 1982 Sep;49(3):167-75
pubmed: 7177597

Auteurs

Andy Haegeman (A)

Infectious Diseases in Animals, Exotic and Particular Diseases, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium.

Ilse De Leeuw (I)

Infectious Diseases in Animals, Exotic and Particular Diseases, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium.

Laurent Mostin (L)

Experimental Center Machelen, Sciensano, Kerklaan 68, B-1830 Machelen, Belgium.

Willem Van Campe (WV)

Experimental Center Machelen, Sciensano, Kerklaan 68, B-1830 Machelen, Belgium.

Laetitia Aerts (L)

EURL for Diseases Caused by Capripox Viruses, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium.

Estelle Venter (E)

Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Onderstepoort 0110, South Africa.
College of Public Health, Medical and Veterinary Sciences, Discipline: Veterinary Science, James Cook University, Townsville, QLD 4811, Australia.

Eeva Tuppurainen (E)

Institut für Internationale Tiergesundheit/One Health, Friedrich-Loeffler-Institut Federal Research Institute for Animal Health, 17489 Greifswald-Insel Riems, Germany.

Claude Saegerman (C)

Fundamental and Applied Research for Animals & Health (FARAH) Center, Research Unit of Epidemiology and Risk Analysis Applied to Veterinary Sciences (UREAR-ULiège), Faculty of Veterinary Medicine, University of Liege, 4000 Liege, Belgium.

Kris De Clercq (K)

Infectious Diseases in Animals, Exotic and Particular Diseases, Sciensano, Groeselenberg 99, B-1180 Brussels, Belgium.

Classifications MeSH